Assignee: Axys Pharmaceuticals, Inc.

Location: South San Francisco, CA
No. of patents: 21

Number	Title	Issue Date
7973037	Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, s...	07/05/2011
7375134	Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, s...	05/20/2008
7226921	Compounds and compositions as cathepsin S inhibitors The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ...	06/05/2007
7064123	Compounds and compositions as cathepsin inhibitors The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ...	06/20/2006
7030116	Compounds and compositions as cathepsin inhibitors The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ...	04/18/2006
7012075	Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, s...	03/14/2006
6977256	Compounds and compositions as cathepsin S inhibitors The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making. ...	12/20/2005
6900237	Sulfonamide compounds as protease inhibitors The present invention relates to novel cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making. ...	05/31/2005
6867200	(Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents ...	03/15/2005
6835727	Cathepsin cysteine protease inhibitors This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as...	12/28/2004
6576630	Compounds and compositions as protease inhibitors The present invention relates to novel alkanoyl-substituted heterocyclic derivatives which are cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making....	06/10/2003
6455502	Compounds and compositions as protease inhibitors The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making....	09/24/2002
6383792	RAQ genes and their uses The invention features polynucleotides encoding novel GTP-binding polypeptides, hereinafter referred to as RAQ polypeptides; expression vectors comprising a RAQ polynucleotide of the invention; isolated cells comprising a RAQ-encoding vector; a transgenic...	05/07/2002
6355460	Metal mediated serine protease inhibitors The present invention relates to serine protease inhibitors having a P site binding moiety and a divalent cation(s) chelating moiety which are pre-prepared as divalent cation(s) complexes or combined with the serine protease in the presence of divalent ca...	03/12/2002
6255091	Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions A method is presented for determining if the inhibition of metal mediated serine proteases can be potentiated by cobalt or zinc ions....	07/03/2001
6114502	Gene family associated with neurosensory defects Nucleic acid compositions are provided that encode a family of mammalian proteins expressed in the retina and brain. Members of the gene family are genetically linked to various neurosensory defects, including cochlear degeneration, peripheral retinal deg...	09/05/2000
6100058	Gap12 genes and their uses Methods for isolating GAP12 genes are provided. The GAP12 nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of ...	08/08/2000
6087485	Asthma related genes A genetic locus associated with asthma is identified. The genes within the locus, ASTH1I and ASTH1J, and the regulatory sequences of the locus are characterized. The genes are used to produce the encoded proteins; in screening for compositions that modula...	07/11/2000
6069010	High throughput gene inactivation with large scale gene targeting The present invention provides a vector system that is useful for the generation of mutations in a recombination-based construction method. The invention further includes the incorporation of mutations generated by the method of the present invention into...	05/30/2000
6022969	Compositions and methods for treating mast-cell mediated conditions Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory disease...	02/08/2000
6017710	RAQ genes and their uses The invention features polynucleotides encoding novel GTP-binding polypeptides, hereinafter referred to as RAQ polypeptides; expression vectors comprising a RAQ polynucleotide of the invention; isolated cells comprising a RAQ-encoding vector; a transgenic...	01/25/2000

PatentStorm

Famous Patents

PatentStorm News

Assignee: Axys Pharmaceuticals, Inc.